Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence ...

STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved ...

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and ...

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who ...

Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Crown Princess Mette-Marit of Norway was photographed looking chic today as she visited the International Library Of Fashion ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.